AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children (ARTEMIS)
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIS
- Sponsors Aimmune Therapeutics
- 08 Aug 2017 According to an Aimmune Therapeutics media release, this trial is expected to support regulatory filings in the Europe in late 2018.
- 05 Jul 2017 According to an Aimmune Therapeutics media release, first patient has been dosed.
- 22 Jun 2017 Status changed from planning to recruiting.